Ruxolitinib for GVHD Prevention
Phase 2a Study of Adding Ruxolitinib With Tacrolimus/Methotrexate Regimen for Graft-versus-Host Disease Prophylaxis in Myeloablative Conditioning Hematopoietic Cell Transplantation in Pediatric and Young Adult Patients
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 40 patients (estimated)
- Sponsors
- City of Hope Medical Center
- Collaborators
- National Cancer Institute (NCI)
- Tags
- Allogeneic Stem Cell Transplant, JAK1 Inhibitor, JAK2 Inhibitor, Tyrosine Kinase (TK) Inhibitor
- Trial Type
- Supportive
- Last Update
- 1 month ago
- SparkCures ID
- 1798
- NCT Identifier
- NCT06128070
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.